Literature DB >> 20494113

Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes.

George Klein1, Eva Klein, Elena Kashuba.   

Abstract

Epstein-Barr virus, EBV, and humans have a common history that reaches back to our primate ancestors. The virus co-evolved with man and has established a largely harmless and highly complex co-existence. It is carried as silent infection by almost all human adults. A serendipitous discovery established that it is the causative agent of infectious mononucleosis. Still, EBV became known first in 1964, in a rare, geographically prevalent malignant lymphoma of B-cell origin, Burkitt lymphoma BL. Its association with a malignancy prompted intensive studies and its capacity to immortalize B-lymphocytes in vitro was soon demonstrated. Consequently EBV was classified therefore as a potentially tumorigenic virus. Despite of this property however, the virus carrier state itself does not lead to malignancies because the transformed cells are recognized by the immune response. Consequently the EBV induced proliferation of EBV carrying B-lymphocytes is manifested only under immunosuppressive conditions. The expression of EBV encoded genes is regulated by the cell phenotype. The virus genome can be found in malignancies originating from cell types other than the B-lymphocyte. Even in the EBV infected B-cell, the direct transforming capacity is restricted to a defined window of differentiation. A complex interaction between virally encoded proteins and B-cell specific cellular proteins constitute the proliferation inducing program. In this short review we touch upon aspects which are the subject of our present work. We describe the mechanisms of some of the functional interactions between EBV encoded and cellular proteins that determine the phenotype of latently infected B-cells. The growth promoting EBV encoded genes are not expressed in the virus carrying BL cells. Still, EBV seems to contribute to the etiology of this tumor by modifying events that influence cell survival and proliferation. We describe a possible growth promoting mechanism in the genesis of Burkitt lymphoma that depends on the presence of EBV. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494113     DOI: 10.1016/j.bbrc.2010.02.146

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

Review 1.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

2.  Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.

Authors:  D Cárdenas; G Vélez; A Orfao; M V Herrera; J Solano; M Olaya; A M Uribe; C Saavedra; M Duarte; M Rodríguez; M López; S Fiorentino; S Quijano
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

3.  The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Authors:  Qian Zhang; Fang Wei; Hong Yi Wang; Xiaobin Liu; Darshan Roy; Qun-Bin Xiong; Shuguang Jiang; Andrew Medvec; Gwenn Danet-Desnoyers; Christopher Watt; Ewa Tomczak; Michael Kalos; James L Riley; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2013-12       Impact factor: 4.307

Review 4.  Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes.

Authors:  Abhik Saha; Erle S Robertson
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

Review 5.  The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma.

Authors:  Ann M Moormann; Cynthia J Snider; Kiprotich Chelimo
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

6.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Epstein-Barr virus genetic variants are associated with multiple sclerosis.

Authors:  Rosella Mechelli; Caterina Manzari; Claudia Policano; Anita Annese; Ernesto Picardi; Renato Umeton; Arianna Fornasiero; Anna Maria D'Erchia; Maria Chiara Buscarinu; Cristina Agliardi; Viviana Annibali; Barbara Serafini; Barbara Rosicarelli; Silvia Romano; Daniela F Angelini; Vito A G Ricigliano; Fabio Buttari; Luca Battistini; Diego Centonze; Franca R Guerini; Sandra D'Alfonso; Graziano Pesole; Marco Salvetti; Giovanni Ristori
Journal:  Neurology       Date:  2015-03-04       Impact factor: 9.910

8.  In ACPA-positive RA patients, antibodies to EBNA35-58Cit, a citrullinated peptide from the Epstein-Barr nuclear antigen-1, strongly cross-react with the peptide β60-74Cit which bears the immunodominant epitope of citrullinated fibrin.

Authors:  M Cornillet; E Verrouil; A Cantagrel; G Serre; L Nogueira
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

9.  Immune surveillance and lymphoid malignancy in immunocompromised host.

Authors:  Patrick L Stevens; Nishitha M Reddy
Journal:  Am J Blood Res       Date:  2013-05-05

Review 10.  Keeping it quiet: chromatin control of gammaherpesvirus latency.

Authors:  Paul M Lieberman
Journal:  Nat Rev Microbiol       Date:  2013-11-06       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.